Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $941.8 million.

  • Ligand Pharmaceuticals' Liabilities and Shareholders Equity rose 54.66% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 21.30%. This contributed to the annual value of $941.8 million for FY2024, which is 19.63% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $941.8 million for FY2024, which was up 19.63% from $787.2 million recorded in FY2023.
  • Ligand Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.4 billion during FY2020, with a 5-year trough of $762.7 million in FY2022.
  • Over the past 3 years, Ligand Pharmaceuticals' median Liabilities and Shareholders Equity value was $787.2 million (recorded in 2023), while the average stood at $830.6 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 41.22% in 2022 and then rose by 19.63% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $1.4 billion in 2020, then dropped by 4.75% to $1.3 billion in 2021, then slumped by 41.22% to $762.7 million in 2022, then climbed by 3.22% to $787.2 million in 2023, then rose by 19.63% to $941.8 million in 2024.